These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8170559)

  • 21. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
    van Gerven JM; Tjon-A-Tsien AM
    Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function.
    Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
    Jaspan J; Maselli R; Herold K; Bartkus C
    Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of retinopathy progression in type 1 diabetes mellitus.
    Cohen RA; Hennekens CH; Christen WG; Krolewski A; Nathan DM; Peterson MJ; LaMotte F; Manson JE
    Am J Med; 1999 Jul; 107(1):45-51. PubMed ID: 10403352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
    Jespersen J; Gram J; Christensen JE
    Haemostasis; 1986; 16(6):453-7. PubMed ID: 3108105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
    Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1983 Oct; 32(10):938-42. PubMed ID: 6225686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P; Attali JR; Gagant S
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy.
    Tkac I; Bril V
    Diabetes Care; 1998 Oct; 21(10):1749-52. PubMed ID: 9773742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
    Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA
    Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of myo-inositol and sorbinil studies.
    Clements RS
    Clin Physiol; 1985; 5 Suppl 5():90-3. PubMed ID: 3938689
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.
    Lehtinen JM; Hyvönen SK; Uusitupa M; Puhakainen E; Halonen T; Kilpeläinen H
    J Neurol; 1986 Jun; 233(3):174-7. PubMed ID: 3522813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with sorbinil--an aldose reductase inhibitor.
    Pitts NE; Vreeland F; Shaw GL; Peterson MJ; Mehta DJ; Collier J; Gundersen K
    Metabolism; 1986 Apr; 35(4 Suppl 1):96-100. PubMed ID: 3083213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A; Carinci F; Graepel JG; Hohman TC; Ferris F; Lachin JM
    Diabetes Care; 1996 Oct; 19(10):1091-6. PubMed ID: 8886554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.